赛升药业：第三季度归母净利润407.33万元，同比下降41.41%

Core Insights - The company reported a revenue of 112 million yuan for Q3 2025, representing a year-on-year increase of 3.50% [1] - The net profit attributable to shareholders decreased by 41.41% to 4.0733 million yuan in Q3 2025 [1] - Basic earnings per share for Q3 2025 stood at 0.01 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 309 million yuan, which is a year-on-year decline of 4.41% [1] - The net profit attributable to shareholders for the first three quarters increased significantly by 152.81% to 51.8596 million yuan [1] - Basic earnings per share for the first three quarters were reported at 0.11 yuan [1]